Drug discovery company Tavros Therapeutics has partnered with screening platform provider OpenBench to identify small molecule modulators for a maximum of five oncology targets within a period of 18 months. The partnership expands their initial collaboration to pursue a first-in-class cancer target.
The collaboration aims to leverage OpenBench's AI chemistry approach and Tavros' synthetic lethality platform to accelerate the discovery of cancer targets. The terms of the agreement include Tavros gaining exclusive access to OpenBench's proprietary screening technology, while OpenBench will receive upfront payment and further compensation upon the successful identification of potent and developable molecules.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.